DTIL Stock Hub: Precision BioSciences News, PBGENE-HBV and DMD

DTIL stock at a glance

Where Precision BioSciences stands now

Precision uses the proprietary ARCUS nuclease platform in its PBGENE-HBV and PBGENE-DMD in vivo gene editing programs. It remains at the clinical stage, with zero quarterly product sales and significant research spending. Its November 5 clinical announcements are meaningful but not registration-stage proof; the financing adds liquidity at the cost of a larger share-equivalent denominator.

Latest DTIL news

DTIL stock catalysts: the dated calendar

• Nov 5-6, 2026Priced

  Offering priced November 5 after the close ($125M gross; ~$116.5M expected net per the Nov 6 filings); closing expected November 6, subject to conditions

• Nov 8, 2026 · 2:15 p.m. MSTScheduled

  AASLD oral presentation of ELIMINATE-B data

• Nov 9, 2026 · 8 a.m. ETScheduled

  Company clinical webcast

• Q1 2027Management target

  Start dosing global HBV Phase 2 ELIMINATE-B2

• H1 / H2 2027Management target

  Successive DMD follow-up assessments

• H2 2027Management target

  Initial open-label HBV Phase 2 observations

03 Why hepatitis B is an appealing, difficult gene-editing target

Chronic hepatitis B involves a persistent pool of viral covalently closed circular DNA in hepatocyte nuclei. That DNA can continue transcribing viral products even when conventional antiviral treatment has suppressed circulating HBV DNA. Nucleos(t)ide analogs are effective suppressive medicines for many patients but do not generally remove the underlying reservoir. This provides a rational target for an editing nuclease: damage the template enough that it no longer maintains virus production. The crucial translational issue is not whether a precise cut can be engineered in a laboratory but whether enough infected cells in human livers receive a suitable editing dose to change the clinical course of disease without unacceptable liver injury.

The 2025 AASLD/IDSA treatment guidance defines functional cure as HBsAg negativity and undetectable HBV DNA off treatment for at least six months. That is not what the November 5 release described achieving. The company's stated ambition includes viral cure and eventually functional cure, and it plans Phase 2 study designs to evaluate those outcomes. A reader should hold two thoughts at once: an early mechanistic result can justify moving forward, and the evidence threshold for declaring patient benefit remains materially higher. Conflating those standards is one of the largest analytical errors possible in a small-cap clinical-stage company.

ARCUS 2022 · Guideline

04 ELIMINATE-B November data: denominators and effects

The Phase 1 ELIMINATE-B cohort described on November 5 included twenty-five treated patients with fifty-nine administrations across four dose levels by the September 28 data cut-off. Twelve participants had detectable pgRNA at baseline and were evaluable for the announced pgRNA response. Eleven of twelve, or approximately ninety-two percent, became undetectable after treatment. Six of six evaluable participants receiving 0.4 milligrams per kilogram achieved that same biomarker endpoint. The one person not fully undetectable in the reported set had received two administrations at 0.65 milligrams per kilogram and exhibited a ninety-five percent pgRNA reduction at cut-off. These figures apply to selected denominators, not the whole treated population.

Matched liver biopsies from two treated participants at 0.4 milligrams per kilogram showed roughly one-log and one-and-a-half-log reductions in cccDNA. One log corresponds to a tenfold reduction; one-and-a-half log approximately a thirtyfold reduction. The company uses the phrase about thirty-fivefold in its release for the larger change. Both formulations are approximate because assay measurement, normalisation and biopsy sampling introduce uncertainty. Biopsies make it more plausible that the blood signal reflects change in the viral reservoir, but two patients cannot support precise rates for a larger population or demonstrate complete clearance in any participant.

HBsAg reductions were reported in all twenty-four evaluable patients, and the maximum reduction approached ninety-four percent at the selected dose. A decrease of this magnitude could be clinically meaningful in a future treatment pathway, but decrease and sustained loss are different endpoints. Some patients may still have detectable antigen even after a large percentage change. Precise baseline HBsAg levels, absolute concentrations, duration, background antiviral use and testing after withdrawal will determine how readily the data transfer to a real-world therapeutic claim. The expected Phase 2 program will test PBGENE-HBV both alone and with an antisense oligonucleotide, so combination effects must not be attributed solely to the editing product.

HBV update · HBV registry

05 HBV safety: infusion effects and liver monitoring

Across the reported fifty-nine administrations, the company described a manageable safety profile with no dose-limiting toxicities. The most common adverse events were infusion-related reactions with timing broadly consistent with lipid-nanoparticle effects. Transient and reversible elevations in alanine aminotransferase and aspartate aminotransferase were also observed. At the selected 0.4 milligram-per-kilogram dose, one delayed elevation after the third administration was reported with peak ALT of 306 units per litre and AST of 278. It resolved without intervention in the company description and occurred without a simultaneous bilirubin increase. That is relevant reassurance but not a reason to disregard the signal.

HBV update

06 What a Phase 2 HBV result would actually have to prove

The planned ELIMINATE-B2 study is intended to evaluate PBGENE-HBV as monotherapy and with an antisense oligonucleotide. The company targets the start of dosing in the first quarter of 2027, with initial open-label data in the second half of the year. Trial initiation and a first open-label efficacy table are operational progress, not necessarily a robust causal comparison. A successful Phase 2 discussion needs to identify the primary objective, baseline patient characteristics, dose frequency, treatment combination, background nucleos(t)ide use, cessation rules and the specified duration of post-treatment monitoring.

HBV update · Guideline

07 Duchenne program: mutation strategy and the delivery challenge

Duchenne muscular dystrophy is caused by pathogenic alterations in the gene encoding dystrophin. Loss of normal dystrophin damages skeletal and cardiac muscle and produces progressive functional impairment. PBGENE-DMD is designed to employ two complementary ARCUS nucleases delivered in one adeno-associated viral vector to remove the exon 45 through exon 55 hotspot from the native gene. The goal is to restore an internally shortened but near-full-length dystrophin product after joining the remaining genetic sequence. The company contrasts this concept with approaches that deliver a separate microdystrophin gene. That design difference is real, but functional advantage remains a clinical hypothesis.

DMD registry

08 FUNCTION-DMD: what the first DSMB decision does and does not say

The first participant in the Phase 1/2 FUNCTION-DMD study received PBGENE-DMD in August 2026. The November 5 announcement covered the first eight weeks of monitoring in that single child. According to the company, there were no serious adverse events or events of special interest in the period, and the independent data safety monitoring board endorsed proceeding with treatment of additional patients in Part 1. That provides the trial with a practical path forward. It demonstrates that the predefined safety hurdle for advancing enrollment was satisfied, based on information available to the board.

DMD DSMB

09 ARCUS as a platform: published studies and evidence boundaries

ARCUS is derived from engineered homing endonucleases and is not the same system as commonly discussed CRISPR-Cas editors. Its compact, single-protein architecture offers potential delivery advantages and sequence specificity that can be re-engineered for different targets. In a peer-reviewed Molecular Therapy study published in 2022, researchers used an ARCUS nuclease targeting HBV DNA in infected primary human hepatocytes and in mouse and non-human primate models containing viral DNA surrogates. Changes in cccDNA and HBsAg in cellular systems, plus editing in experimental animals, supported the biological rationale. They were not patient cure outcomes and relied in part on models that cannot recreate every feature of chronic human HBV infection.

ARCUS 2022 · ARCUS 2025

10 Third-quarter financial quality and actual operating economics

Precision's September-quarter income statement reported zero revenue, $12.745 million of research and development expense, $7.683 million of general and administrative expense, and a $20.428 million operating loss. The GAAP net loss was only $7.586 million. The dominant reason was a $12.724 million gain in the fair value of warrant liabilities, a non-cash mark-to-market adjustment that does not finance a single trial visit. A reader who focuses on the net loss alone would incorrectly infer a much smaller operating deficit. Operating expense and actual cash flow provide a better starting point for assessing recurring resource needs, although even operating expense is not a cash-flow statement.

At September 30 the balance sheet listed $108.034 million of cash, cash equivalents and restricted cash, $78.305 million in working capital, $120.376 million in assets, $68.601 million of liabilities and $51.775 million in equity. Liabilities included a $22.424 million loan payable and a $23.969 million warrant fair-value liability. The latter is not identical to a scheduled cash repayment of that amount. Management has projected a runway through 2028 using existing resources, operational discipline and potential access to financing. Readers should treat that horizon as an estimate sensitive to trial spending, not as a minimum guaranteed cash term.

SEC 10-Q · Q3 results

11 November offering: pricing, closing and dilution arithmetic

The November 5 transaction was an underwritten offering priced at $7.75 for each of 10,235,077 common shares and $7.749995 for each of 5,893,964 pre-funded warrants, with a $0.000005 exercise price for the latter. The combined economics produce approximately $125.0 million of gross proceeds before underwriting discounts, commissions and other expenses. The expected closing was on or about November 6, subject to customary conditions. As of the November 6 filings, the stated fact is pricing. It is not correct to put an additional $125 million of cash onto the September 30 balance sheet, and even after closing the amount actually received will be lower than gross proceeds.

The simple economic share equivalent count is 16,129,041, obtained by adding new common shares and the shares underlying the pre-funded warrants. Relative to the 27,893,065 common shares outstanding on September 30, the proposed number represents approximately 57.8 percent more equivalents. If one uses only that base and those new equivalents, the enlarged denominator is 44,022,106, of which the new instruments constitute about 36.6 percent. These are illustrative arithmetic calculations, not the company's final fully diluted share count. They exclude other warrants and options, as well as any issuance or repurchase between September 30 and settlement.

Offering · SEC 10-Q

12 Market structure: liquidity, short interest and event reactions

DTIL trades on the Nasdaq Capital Market, and biotechnology events can produce large moves on relatively limited volume. The November 4 regular close was $8.12, compared with $6.97 the prior day. This does not show how investors will value the HBV data or the equity issue after the two announcements. Overnight indications, morning spikes and subsequent settlement prices are different market observations. Price reference: the November 6, 2026 regular-session close.

SEC 10-Q

13 Catalyst map for the next twelve months

The closest financial event is expected settlement of the equity financing around November 6. The closest scientific presentation is AASLD on November 8, followed by a company investor webcast on November 9. Each has a specific question: the filing must confirm terms and net cash, while the scientific events must clarify the same clinical dataset's denominators and methods. A new table identifying exactly how many patients maintained pgRNA suppression at six, nine and twelve months would be more valuable than an additional adjectival description of durability. Paired biopsies should be interpreted with their before-and-after levels, sampling methods and assay limitations.

HBV update · DMD DSMB

14 Scenarios: bull, base and bear without price targets

In a favorable scientific and financial scenario, the AASLD presentation strengthens confidence in the 0.4 milligram-per-kilogram dose through clear and durable human biomarker data, the company completes its financing, and Phase 2 enrollment begins broadly on the announced schedule. More participants maintain suppression, liver findings remain directionally consistent and Phase 2 eventually supplies evidence of off-treatment viral control. The DMD program also advances without new major safety problems and demonstrates measurable production of near-full-length dystrophin with a plausible relationship to function. In that combination the company could create value through differentiated products, licensing or future development options. None of these outcomes is yet proven.

In an adverse scenario, the apparent HBV biomarker benefit does not translate into sustained HBsAg loss and off-treatment HBV DNA control; remaining reservoir or integrated viral sequences undercut durable functional benefit. Alternatively, liver inflammation, infusion reactions or other safety issues limit repeat dosing. AAV-related toxicity or insufficient dystrophin editing causes delays or weak results in Duchenne. Trial costs rise, and additional dilution is required before an approvable endpoint is reached. Clinical programs can fail even when a mechanism is scientifically elegant. A conservative approach asks which observation would invalidate the thesis, not merely which future announcement could create excitement.

HBV update · DMD DSMB

15 Risk ledger and evidence falsifiers

Clinical translation risk is the largest nonfinancial variable. For HBV the primary distinction is between mechanistic markers and the sustained off-treatment state patients actually need. A limited number of tissue biopsies, short follow-up windows, missing values and subgroup selection can make a response appear cleaner than it will in a heterogeneous Phase 2 population. The correct response is to request the denominator and protocol definition behind every percentage, not simply to dismiss the data. Positive mechanistic data are meaningful and still may be insufficient for regulatory approval.

HBV update

16 Research FAQ: the questions behind the headlines

Has the company demonstrated a hepatitis B cure? No. The November 5 public data describe early Phase 1 reductions in pgRNA, HBsAg and liver cccDNA. The defined functional-cure outcome involving HBsAg negativity and undetectable HBV DNA off treatment for at least six months was not shown as achieved in that announcement. The selected 0.4 milligram-per-kilogram dose and planned Phase 2 development are legitimate progress toward testing this hypothesis. A person reading a headline about cccDNA elimination should still check which assay was used, how many matched biopsies were available and how long patients have remained under observation.

How much cash does the company have after the offering? At the report's date the verified balance-sheet observation is $108.034 million of cash, equivalents and restricted cash as of September 30, 2026. The November 5 company release priced an approximately $125 million gross financing, with an expected closing on or around November 6. Cash after closing cannot be established from pricing alone because final settlement, fees, working capital changes and other events must be taken into account. A later filing can update liquidity; gross proceeds are not cash in hand until settlement is confirmed.

Guideline · DMD DSMB · Offering

Merlintrader Health Score · $DTIL

Editorial assessment as of November 6, 2026, on filings to the quarter ended September 30, 2026, and the company announcements of November 5. The score describes financial and operational robustness over twelve to eighteen months. It is not a rating, a target price or an indication to buy or sell.

Red flags

• No revenue in the third quarter of 2026 and an operating loss of $20.4 million; the $7.6 million net loss was reduced by a $12.7 million non-cash warrant gain.
• The November offering of 10,235,077 shares and pre-funded warrants for 5,893,964 shares adds about 16.1 million share equivalents, roughly 58% of the September 30 share count.
• The offering was priced on November 5 after the close and closing was expected on November 6, subject to conditions; gross proceeds are not cash in hand until settlement is confirmed.
• The HBV results are early Phase 1 biomarkers; a functional cure has not been shown, and paired liver biopsies come from two participants.
• The DMD safety decision rests on one child and eight weeks of follow-up.
• In vivo gene editing carries delivery, durability and safety risks that only larger and longer trials can measure.